1
|
Banerjee P, Mehta AR, Nirujogi RS, Cooper J, James OG, Nanda J, Longden J, Burr K, McDade K, Salzinger A, Paza E, Newton J, Story D, Pal S, Smith C, Alessi DR, Selvaraj BT, Priller J, Chandran S. Cell-autonomous immune dysfunction driven by disrupted autophagy in C9orf72-ALS iPSC-derived microglia contributes to neurodegeneration. Sci Adv 2023; 9:eabq0651. [PMID: 37083530 PMCID: PMC10121169 DOI: 10.1126/sciadv.abq0651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Accepted: 03/20/2023] [Indexed: 05/03/2023]
Abstract
Although microglial activation is widely found in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), the underlying mechanism(s) are poorly understood. Here, using human-induced pluripotent stem cell-derived microglia-like cells (hiPSC-MG) harboring the most common ALS/FTD mutation (C9orf72, mC9-MG), gene-corrected isogenic controls (isoC9-MG), and C9orf72 knockout hiPSC-MG (C9KO-MG), we show that reduced C9ORF72 protein is associated with impaired phagocytosis and an exaggerated immune response upon stimulation with lipopolysaccharide. Analysis of the C9ORF72 interactome revealed that C9ORF72 interacts with regulators of autophagy and functional studies showed impaired initiation of autophagy in mC9-MG and C9KO-MG. Coculture studies with motor neurons (MNs) demonstrated that the autophagy deficit in mC9-MG drives increased vulnerability of mC9-MNs to excitotoxic stimulus. Pharmacological activation of autophagy ameliorated both cell-autonomous functional deficits in hiPSC-MG and MN death in MG-MN coculture. Together, these findings reveal an important role for C9ORF72 in regulating immune homeostasis and identify dysregulation in myeloid cells as a contributor to neurodegeneration in ALS/FTD.
Collapse
Affiliation(s)
- Poulomi Banerjee
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Arpan R. Mehta
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Raja S. Nirujogi
- Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
| | - James Cooper
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Owen G. James
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Jyoti Nanda
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - James Longden
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Karen Burr
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Karina McDade
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Edinburgh Brain Bank, Academic Department of Neuropathology, University of Edinburgh, Edinburgh, UK
- Edinburgh Pathology, University of Edinburgh, Edinburgh, UK
| | - Andrea Salzinger
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Evdokia Paza
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Judith Newton
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - David Story
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Suvankar Pal
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Colin Smith
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
- Edinburgh Brain Bank, Academic Department of Neuropathology, University of Edinburgh, Edinburgh, UK
- Edinburgh Pathology, University of Edinburgh, Edinburgh, UK
| | - Dario R. Alessi
- Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
| | - Bhuvaneish T. Selvaraj
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - Josef Priller
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Department of Psychiatry and Psychotherapy; School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany
- Neuropsychiatry, Charité–Universitätsmedizin Berlin and DZNE, Charitéplatz 1, 10117 Berlin, Germany
| | - Siddharthan Chandran
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh EH16 4SB, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh EH16 4SB, UK
| |
Collapse
|
2
|
Nanda J, Verma N, Mani M. A Mechanistic Review on Phytomedicine and Natural Products in the Treatment of Diabetes. Curr Diabetes Rev 2022; 19:44-54. [PMID: 36567295 DOI: 10.2174/1573399819666221222155055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 10/20/2022] [Accepted: 10/31/2022] [Indexed: 12/27/2022]
Abstract
Diabetes mellitus is a metabolic syndrome of excess glucose levels in the blood. It may be due to glucose intolerance by the tissues and inadequate insulin production from pancreatic β-cells. However, diabetic complication includes cardiovascular and kidney diseases, eye, skin, and foot complications, and neuropathy. The intention behind writing this article was to gather recent information regarding the use of ancient traditional medicinal plants having recent importance in treating diabetes. Several therapies are available for curing the condition based on severity and type of diabetes. Although pharmacological treatments are effective and economical, drugs are associated with unwanted side effects and physiological complications on long-term use. Interestingly, herbs and herbal plants have been used since ancient times against diabetes worldwide. Its importance still exists due to medicinal plants' effectiveness and safety profile in treating various diseases. In this article, we searched online databases, including PUBMED, SCOPUS, MEDLINE, and traditional resources, for collecting information regarding the use of plants against diabetes. We described the pathophysiology of the disease and incorporated plant sources and their chemical constituents responsible for antidiabetic activity with their mechanism in reducing blood glucose levels. The present article may be very helpful for researchers and professionals whose work is inclined towards diabetes and in search of lead compounds for the development of a suitable drug.
Collapse
Affiliation(s)
- Jyoti Nanda
- Pharmacy Academy, IFTM University, Moradabad, U.P., India-244102
| | - Neeraj Verma
- Hygia Institute of Pharmaceutical Education and Research, Lucknow, U.P., India-226620
| | - Munesh Mani
- Pharmacy Academy, IFTM University, Moradabad, U.P., India-244102
| |
Collapse
|
3
|
Achanna KS, Nanda J. Evaluation and management of abnormal uterine bleeding. Med J Malaysia 2022; 77:374-383. [PMID: 35638495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Abnormal uterine bleeding (AUB) is one of the commonest complaints of women in reproductive age and non-gravid state that brings them to the attention of the primary care doctor or the gynaecologist. Anovulation without any medical illness or pelvic pathology seems to be the common cause. Bleeding due to a wide variation in pathology both inside and outside the reproductive tract can be termed as anovulatory bleeding. Therefore, it is mandatory to elicit a focused menstrual history and appropriate evaluation followed by a pelvic examination. This includes a vaginal speculum examination to differentiate anovulatory bleeding from other causes of bleeding. In contrast, Heavy menstrual bleeding (HMB) is referred to as an ovulatory bleeding exceeding 8 days duration and is often caused by uterine fibroids or adenomyosis, a copper IUD or coagulation disorders. PALM-COEIN classification is a system designed by the Federation Internationale de Gynaecologie et d'Obstetrique to define the precise underlying causes of AUB. Aetiology of AUB can be classified as the following acronym "PALM-COEIN": Polyp, Adenomyosis, Leiomyoma, Malignancy and hyperplasia, Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic and Not yet classified. AUB describes a range of symptoms, such as HMB, intermenstrual bleeding (IMB) and a combination of both heavy and prolonged menstrual bleeding (MB). Dysfunctional uterine bleeding (DUB) and menorrhagia are now better described as AUB. Newborn girls sometimes spot for a few days after birth, due to placental oestrogenic stimulation of the endometrium in utero.
Collapse
Affiliation(s)
- K S Achanna
- Mahsa University, Jalan SP2, Bandar Saujana Putra, Jenjarom, Kuala Langat, Selangor, Malaysia.
| | - J Nanda
- Mahsa University, Jalan SP2, Bandar Saujana Putra, Jenjarom, Kuala Langat, Selangor, Malaysia
| |
Collapse
|
4
|
Ross JA, Vissers JPC, Nanda J, Stewart GD, Husi H, Habib FK, Hammond DE, Gethings LA. The influence of hypoxia on the prostate cancer proteome. Clin Chem Lab Med 2021; 58:980-993. [PMID: 31940282 DOI: 10.1515/cclm-2019-0626] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 09/11/2019] [Indexed: 12/11/2022]
Abstract
Prostate cancer accounts for around 15% of male deaths in Western Europe and is the second leading cause of cancer death in men after lung cancer. Mounting evidence suggests that prostate cancer deposits exist within a hypoxic environment and this contributes to radio-resistance thus hampering one of the major therapies for this cancer. Recent reports have shown that nitric oxide (NO) donating non-steroidal anti-inflammatory drugs (NSAIDs) reduced tumour hypoxia as well as maintaining a radio-sensitising/therapeutic effect on prostate cancer cells. The aim of this study was to evaluate the impact of hypoxia on the proteome of the prostate and to establish whether NO-NSAID treatment reverted the protein profiles back to their normoxic status. To this end an established hormone insensitive prostate cancer cell line, PC-3, was cultured under hypoxic and normoxic conditions before and following exposure to NO-NSAID in combination with selected other common prostate cancer treatment types. The extracted proteins were analysed by ion mobility-assisted data independent acquisition mass spectrometry (MS), combined with multivariate statistical analyses, to measure hypoxia-induced alterations in the proteome of these cells. The analyses demonstrated that under hypoxic conditions there were well-defined, significantly regulated/differentially expressed proteins primarily involved with structural and binding processes including, for example, TUBB4A, CIRP and PLOD1. Additionally, the exposure of hypoxic cells to NSAID and NO-NSAID agents, resulted in some of these proteins being differentially expressed; for example, both PCNA and HNRNPA1L were down-regulated, corresponding with disruption in the nucleocytoplasmic shuttling process.
Collapse
Affiliation(s)
- James A Ross
- Tissue Injury and Repair Group, University of Edinburgh, Edinburgh, UK
| | | | - Jyoti Nanda
- Tissue Injury and Repair Group, University of Edinburgh, Edinburgh, UK.,Prostate Research Group, University of Edinburgh, Edinburgh, UK
| | - Grant D Stewart
- Department of Surgery, University of Cambridge, Cambridge, UK
| | - Holger Husi
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
| | - Fouad K Habib
- Tissue Injury and Repair Group, University of Edinburgh, Edinburgh, UK.,Prostate Research Group, University of Edinburgh, Edinburgh, UK
| | - Dean E Hammond
- Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK
| | - Lee A Gethings
- Waters Corporation, Wilmslow, UK.,Manchester Institute of Biotechnology, Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| |
Collapse
|
5
|
Achanna S, Nanda J, Paramjothi P. Reconsideration of planned vaginal breech delivery in selected cases. Med J Malaysia 2021; 76:390-394. [PMID: 34031339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
INTRODUCTION The debate surrounding the management of term breech presentation (BP) has resulted in the presence of a multitude of guidelines, reviews, and directives. The vaginal delivery of a breech baby requires sound obstetric skills since approximately 3-4% of babies at term are breech presentations. BP is the commonest of all malpresentations. However, expertise required to deliver breech babies vaginally has virtually disappeared. There is no convincing evidence that Caesarean Section (CS) is better than assisted vaginal delivery when conducted in appropriate settings, with experienced obstetricians and strict prevailing protocols. Unfortunately, planned vaginal breech delivery (VBD) is becoming an uncommon event. This has led to fewer opportunities for obstetric residents to master the skills of vaginal birth of breech presentations. MATERIALS AND METHODS The BP has always been a challenge for obstetricians, due to special skills required to deliver the breech safely. In addition, the immediate perinatal outcome, in terms of APGAR scores and acid-base status of the breech babies is of great concern. Thus, in 2000, in order to provide more evidence-based data, the Term Breech Trial (TBT) was published which compared the outcome of VBD with planned CS. In their 2003 Clinical Guideline, the National Institute for Health and Clinical Excellence (NICE) recommended external cephalic version (ECV) for breech presentation at 36 weeks of gestation a ns elective CS if the procedure is declined or failed. The first edition, Green-top Guidelines by the Royal College of Obstetricians and Gynaecologists (RCOG) regarding the breech delivery was first published in 1999 and revised in 2001, 2006 (Nos. 20a and 20b) and March 2017. In 2020, the Guideline Committee meeting decided on a further revision and deferred the decision for further 3 years (2023). The aim of this Guideline is to aid decision making regarding the route of delivery and choice of various techniques used during delivery. In March 2005, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) issued a formal statement concerning breech delivery at term. Through their Committee on Obstetric Practice, the American College of Obstetricians and Gynecologists (ACOG) issued a Committee Opinion paper on "Mode of term singleton breech delivery" in 2006. RESULTS Almost immediately, the medical community all over the world embraced the conclusions of the trial highlighting the superiority of outcomes in planned CS compared to VBD in terms of maternal, neonatal mortality and morbidity. Clinicians, in consultation with their patients, must make the final decisions regarding mode of breech delivery in the light of the updated clinical guidelines and committee opinions for a rational choice for the mode of delivery. CONCLUSION There is a place for planned VBD, the prerequisites are: strict case selection, operator skills and vigilant intrapartum monitoring. Provision of basic skills training by utilizing birthing pelvic models and mannikins, hands-on practice of External Cephalic Version (ECV) in clinical settings, may result in larger reduction in the risk of CS.
Collapse
Affiliation(s)
- S Achanna
- MAHSA University, Saujana Putra Campus, Jenjarom, Selangor, Malaysia.
| | - J Nanda
- MAHSA University, Saujana Putra Campus, Jenjarom, Selangor, Malaysia
| | - P Paramjothi
- MAHSA University, Saujana Putra Campus, Jenjarom, Selangor, Malaysia
| |
Collapse
|
6
|
Perkins EM, Burr K, Banerjee P, Mehta AR, Dando O, Selvaraj BT, Suminaite D, Nanda J, Henstridge CM, Gillingwater TH, Hardingham GE, Wyllie DJA, Chandran S, Livesey MR. Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Mol Neurodegener 2021; 16:13. [PMID: 33663561 PMCID: PMC7931347 DOI: 10.1186/s13024-021-00433-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 02/14/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Physiological disturbances in cortical network excitability and plasticity are established and widespread in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those harbouring the C9ORF72 repeat expansion (C9ORF72RE) mutation - the most common genetic impairment causal to ALS and FTD. Noting that perturbations in cortical function are evidenced pre-symptomatically, and that the cortex is associated with widespread pathology, cortical dysfunction is thought to be an early driver of neurodegenerative disease progression. However, our understanding of how altered network function manifests at the cellular and molecular level is not clear. METHODS To address this we have generated cortical neurons from patient-derived iPSCs harbouring C9ORF72RE mutations, as well as from their isogenic expansion-corrected controls. We have established a model of network activity in these neurons using multi-electrode array electrophysiology. We have then mechanistically examined the physiological processes underpinning network dysfunction using a combination of patch-clamp electrophysiology, immunocytochemistry, pharmacology and transcriptomic profiling. RESULTS We find that C9ORF72RE causes elevated network burst activity, associated with enhanced synaptic input, yet lower burst duration, attributable to impaired pre-synaptic vesicle dynamics. We also show that the C9ORF72RE is associated with impaired synaptic plasticity. Moreover, RNA-seq analysis revealed dysregulated molecular pathways impacting on synaptic function. All molecular, cellular and network deficits are rescued by CRISPR/Cas9 correction of C9ORF72RE. Our study provides a mechanistic view of the early dysregulated processes that underpin cortical network dysfunction in ALS-FTD. CONCLUSION These findings suggest synaptic pathophysiology is widespread in ALS-FTD and has an early and fundamental role in driving altered network function that is thought to contribute to neurodegenerative processes in these patients. The overall importance is the identification of previously unidentified defects in pre and postsynaptic compartments affecting synaptic plasticity, synaptic vesicle stores, and network propagation, which directly impact upon cortical function.
Collapse
Affiliation(s)
- Emma M. Perkins
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
| | - Karen Burr
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
| | - Poulomi Banerjee
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
| | - Arpan R. Mehta
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
| | - Owen Dando
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, EH8 9XD UK
| | - Bhuvaneish T. Selvaraj
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
| | - Daumante Suminaite
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
| | - Jyoti Nanda
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
| | - Christopher M. Henstridge
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, DD1 9SY UK
| | - Thomas H. Gillingwater
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
| | - Giles E. Hardingham
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, EH8 9XD UK
| | - David J. A. Wyllie
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, EH8 9XD UK
- Centre for Brain Development and Repair, inStem, Bangalore, 560065 India
| | - Siddharthan Chandran
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB UK
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, EH16 4SB UK
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, EH8 9XD UK
- Centre for Brain Development and Repair, inStem, Bangalore, 560065 India
| | - Matthew R. Livesey
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD UK
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, EH8 9XD UK
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, S10 2HQ UK
| |
Collapse
|
7
|
Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, Story D, McDade K, Smith C, Morton NM, Mahad DJ, Hardingham GE, Chandran S, Selvaraj BT. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol 2021; 141:257-279. [PMID: 33398403 PMCID: PMC7847443 DOI: 10.1007/s00401-020-02252-5] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 11/30/2020] [Accepted: 12/09/2020] [Indexed: 12/11/2022]
Abstract
Axonal dysfunction is a common phenotype in neurodegenerative disorders, including in amyotrophic lateral sclerosis (ALS), where the key pathological cell-type, the motor neuron (MN), has an axon extending up to a metre long. The maintenance of axonal function is a highly energy-demanding process, raising the question of whether MN cellular energetics is perturbed in ALS, and whether its recovery promotes axonal rescue. To address this, we undertook cellular and molecular interrogation of multiple patient-derived induced pluripotent stem cell lines and patient autopsy samples harbouring the most common ALS causing mutation, C9orf72. Using paired mutant and isogenic expansion-corrected controls, we show that C9orf72 MNs have shorter axons, impaired fast axonal transport of mitochondrial cargo, and altered mitochondrial bioenergetic function. RNAseq revealed reduced gene expression of mitochondrially encoded electron transport chain transcripts, with neuropathological analysis of C9orf72-ALS post-mortem tissue importantly confirming selective dysregulation of the mitochondrially encoded transcripts in ventral horn spinal MNs, but not in corresponding dorsal horn sensory neurons, with findings reflected at the protein level. Mitochondrial DNA copy number was unaltered, both in vitro and in human post-mortem tissue. Genetic manipulation of mitochondrial biogenesis in C9orf72 MNs corrected the bioenergetic deficit and also rescued the axonal length and transport phenotypes. Collectively, our data show that loss of mitochondrial function is a key mediator of axonal dysfunction in C9orf72-ALS, and that boosting MN bioenergetics is sufficient to restore axonal homeostasis, opening new potential therapeutic strategies for ALS that target mitochondrial function.
Collapse
Affiliation(s)
- Arpan R Mehta
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Jenna M Gregory
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
- MRC Edinburgh Brain Bank, Academic Department of Neuropathology, University of Edinburgh, Edinburgh, UK
- Edinburgh Pathology, University of Edinburgh, Edinburgh, UK
| | - Owen Dando
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Roderick N Carter
- University/British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
| | - Karen Burr
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
| | - Jyoti Nanda
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
| | - David Story
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
| | - Karina McDade
- MRC Edinburgh Brain Bank, Academic Department of Neuropathology, University of Edinburgh, Edinburgh, UK
| | - Colin Smith
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
- MRC Edinburgh Brain Bank, Academic Department of Neuropathology, University of Edinburgh, Edinburgh, UK
- Edinburgh Pathology, University of Edinburgh, Edinburgh, UK
| | - Nicholas M Morton
- University/British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
| | - Don J Mahad
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK
| | - Giles E Hardingham
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Siddharthan Chandran
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK.
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK.
- Centre for Brain Development and Repair, inStem, Bangalore, India.
| | - Bhuvaneish T Selvaraj
- UK Dementia Research Institute at University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK.
- Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK.
| |
Collapse
|
8
|
Nashim A, Pany S, Parida KM, Nanda J. La
2
Ti
2
O
7
As Nanometric Electrode Material: An Emerging Candidate For Supercapacitor Performance. ChemistrySelect 2019. [DOI: 10.1002/slct.201903227] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Amtul Nashim
- Centre for Nano Science and Nano TechnologyInstitute of Technical Education and ResearchSiksha ‘O' Anusandhan (Deemed to be University) Bhubaneswar 751030 India
| | - Soumyashree Pany
- Centre for Nano Science and Nano TechnologyInstitute of Technical Education and ResearchSiksha ‘O' Anusandhan (Deemed to be University) Bhubaneswar 751030 India
| | - K. M. Parida
- Centre for Nano Science and Nano TechnologyInstitute of Technical Education and ResearchSiksha ‘O' Anusandhan (Deemed to be University) Bhubaneswar 751030 India
| | - J. Nanda
- Department of PhysicsInstitute of Technical Education and ResearchSiksha ‘O' Anusandhan (Deemed to be University) Bhubaneswar 751030 India
| |
Collapse
|
9
|
Abstract
Over the past several years, there has been substantial progress in the field of regenerative medicine, which has enabled new possibilities for research and clinical application. For example, there are ongoing efforts directed at generating functional hepatocytes from adult-derived pluripotent cells for toxicity screening, generating disease models or, in the longer term, for the treatment of liver failure. In the present review, the authors summarise recent developments in regenerative medicine and pluripotent stem cells, the methods and tissues used for reprogramming and the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells. In addition, the hepatic disease models developed using iPSC technologies are discussed, as well as the potential for gene editing.
Collapse
Affiliation(s)
- Anwar A Palakkan
- Tissue Injury and Repair Group, Clinical Sciences, Edinburgh Medical School, University of Edinburgh, EH16 4SB Edinburgh, UK
| | - Jyoti Nanda
- Tissue Injury and Repair Group, Clinical Sciences, Edinburgh Medical School, University of Edinburgh, EH16 4SB Edinburgh, UK
| | - James A Ross
- Tissue Injury and Repair Group, Clinical Sciences, Edinburgh Medical School, University of Edinburgh, EH16 4SB Edinburgh, UK
| |
Collapse
|
10
|
Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA, Riddick AC, Berney D, Bex A, Aitchison M, Overton IM, Harrison DJ, Powles T. Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. Clin Cancer Res 2015; 21:4212-23. [DOI: 10.1158/1078-0432.ccr-15-0207] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Accepted: 05/03/2015] [Indexed: 11/16/2022]
|
11
|
Stewart G, Laird A, O'Mahony F, Eory L, Lubbock A, Nanda J, O'Donnell M, Mackay A, Mullen P, McNeill A, Riddick A, Aitchison M, Berney D, Bex A, Overton I, Harrison DJ, Powles T. The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.4_suppl.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
408 Background: The purpose of this work was to investigate the effect of sunitinib on tumour biomarkers and assess intratumoural heterogeneity in metastatic clear cell renal cancer (mRCC). Primary tumours and metastatic sites were examined. Methods: Multiple fresh frozen tissue samples (median=4) were taken from sunitinib naive (n=23) and sunitinib treated (18 weeks at sunitinib 50mg) patients (n=27) with mRCC. Tissue was taken from the primary renal tumours. Multiple analysis of DNA (aCGH), mRNA (Illumina Beadarray) and protein lysates (reverse phase protein array) were performed on each tumour sample. Analysis of metastatic tissue occurred where possible (n=4). A cohort of matched untreated and sunitinib/pazopanib treated paraffin embedded mRCC samples from 3 clinical trials was used for validation with automated quantitative analysis. Results: Treated and untreated patient had similar patient characteristics. Significant intratumoural heterogeneity in DNA, RNA and protein occurred. Sunitinib was associated with increased intratumoural heterogeneity in protein expression (p<0.05), but not DNA or RNA. Despite this heterogeneity, significant changes to protein expression with sunitinib occurred. Four proteins changed significantly in terms of both expression and variance with sunitinib (BCL2, MLH1, CAIX and mTOR; p<0.05 for each). Elevation of CAIX expression in sunitinib treated patients was confirmed in the validation cohort (p=0.01). Low levels of CAIX correlated with poor outcome in treated samples (HR=0.26, 95% CI: 0.11-0.61, p=0.001). A positive correlation between protein expression in the primary tumour and metastatic sites occurred. Individual metastasis within patients exhibited a variable radiological response to therapy, which was equally marked in the genetically more homogeneous primary tumours. Conclusions: Intratumoural heterogeneity occurs on many levels in mRCC. Sunitinib is associated with increase in protein heterogeneity. Despite this, upregulation of CAIX is a potential prognostic biomarker.
Collapse
Affiliation(s)
| | | | | | - Lel Eory
- Roslin Institute, Edinburgh, United Kingdom
| | | | - Jyoti Nanda
- University of Edinburgh, Edinburgh, United Kingdom
| | | | - Alan Mackay
- The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Peter Mullen
- University of St. Andrews, St. Andrews, United Kingdom
| | - Alan McNeill
- University of Edinburgh, Edinburgh, United Kingdom
| | - Antony Riddick
- Department of Urology, Addenbrooke's Hospital, Cambridge, United Kingdom
| | | | | | - Axel Bex
- The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Ian Overton
- MRC Human Genetics Unit, Edinburgh, United Kingdom
| | | | - Tom Powles
- Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| |
Collapse
|
12
|
Laird A, O'Mahony FC, Nanda J, Riddick ACP, O'Donnell M, Harrison DJ, Stewart GD. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One 2013; 8:e60483. [PMID: 23577117 PMCID: PMC3618228 DOI: 10.1371/journal.pone.0060483] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2012] [Accepted: 02/26/2013] [Indexed: 01/16/2023] Open
Abstract
Renal cell carcinoma (RCC) is the most deadly of urological malignancies. Metastatic disease affects one third of patients at diagnosis with a further third developing metastatic disease after extirpative surgery. Heterogeneity in the clinical course ensures predicting metastasis is notoriously difficult, despite the routine use of prognostic clinico-pathological parameters in risk stratification. With greater understanding of pathways involved in disease pathogenesis, a number of biomarkers have been shown to have prognostic significance, including Ki67, p53, vascular endothelial growth factor receptor 1 (VEGFR1) and ligand D (VEGFD), SNAIL and SLUG. Previous pathway analysis has been from study of the primary tumour, with little attention to the metastatic tumours which are the focus of targeted molecular therapies. As such, in this study a tissue microarray from 177 patients with primary renal tumour, renal vein tumour thrombus and/or RCC metastasis has been created and used with Automated Quantitative Analysis (AQUA) of immunofluorescence to study the prognostic significance of these markers in locally advanced and metastatic disease. Furthermore, this has allowed assessment of differential protein expression between the primary tumours, renal vein tumour thrombi and metastases. The results demonstrate that clinico-pathological parameters remain the most significant predictors of cancer specific survival; however, high VEGFR1 or VEGFD can predict poor cancer specific survival on univariate analysis for locally advanced and metastatic disease. There was significantly greater expression of Ki67, p53, VEGFR1, SLUG and SNAIL in the metastases compared with the primary tumours and renal vein tumour thrombi. With the exception of p53, these differences in protein expression have not been shown previously in RCC. This confirms the importance of proliferation, angiogenesis and epithelial to mesenchymal transition in the pathogenesis and metastasis of RCC. Importantly, this work highlights the need for further pathway analysis of metastatic tumours for overcoming drug resistance and developing new therapies.
Collapse
Affiliation(s)
- Alexander Laird
- MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M, Faratian D, Powles T, Harrison DJ, Stewart GD. The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers. J Vis Exp 2013:50221. [PMID: 23380956 DOI: 10.3791/50221] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Currently there is no curative treatment for metastatic clear cell renal cell cancer, the commonest variant of the disease. A key factor in this treatment resistance is thought to be the molecular complexity of the disease. Targeted therapy such as the tyrosine kinase inhibitor (TKI)-sunitinib have been utilized, but only 40% of patients will respond, with the overwhelming majority of these patients relapsing within 1 year. As such the question of intrinsic and acquired resistance in renal cell cancer patients is highly relevant. In order to study resistance to TKIs, with the ultimate goal of developing effective, personalized treatments, sequential tissue after a specific period of targeted therapy is required, an approach which had proved successful in chronic myeloid leukaemia. However the application of such a strategy in renal cell carcinoma is complicated by the high level of both inter- and intratumoral heterogeneity, which is a feature of renal cell carcinoma as well as other solid tumors. Intertumoral heterogeneity due to transcriptomic and genetic differences is well established even in patients with similar presentation, stage and grade of tumor. In addition it is clear that there is great morphological (intratumoral) heterogeneity in RCC, which is likely to represent even greater molecular heterogeneity. Detailed mapping and categorization of RCC tumors by combined morphological analysis and Fuhrman grading allows the selection of representative areas for proteomic analysis. Protein based analysis of RCC is attractive due to its widespread availability in pathology laboratories; however, its application can be problematic due to the limited availability of specific antibodies. Due to the dot blot nature of the Reverse Phase Protein Arrays (RPPA), antibody specificity must be pre-validated; as such strict quality control of antibodies used is of paramount importance. Despite this limitation the dot blot format does allow assay miniaturization, allowing for the printing of hundreds of samples onto a single nitrocellulose slide. Printed slides can then be analyzed in a similar fashion to Western analysis with the use of target specific primary antibodies and fluorescently labelled secondary antibodies, allowing for multiplexing. Differential protein expression across all the samples on a slide can then be analyzed simultaneously by comparing the relative level of fluorescence in a more cost-effective and high-throughput manner.
Collapse
|
15
|
Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A, McNeill A, Aitchison M, Berney D, Peters J, Rockall A, Sahdev A, Bex A, Faratian D, Chowdhury S, Harrison D, Overton I, Powles T. Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.5_suppl.388] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
388 Background: To investigate acquired resistance of clear cell renal cell cancer (ccRCC) patients to sunitinib and develop personalised treatment strategies, sequential tissue after a specific period of targeted therapy is required. This approach has proven successful with targeted therapy in chronic myeloid leukaemia; however, we are concerned that extensive tumour heterogeneity occurs in ccRCC. In this study we evaluated heterogeneity and differential protein expression in sunitinib treated and untreated ccRCC samples using high-throughput proteomics. Methods: Fresh frozen tissue was obtained from 27 sunitinib naïve ccRCC specimens and 27 nephrectomy samples from patients treated with neoadjuvant sunitinib (18 weeks) as part of the SuMR trial. From each tumour frozen sections were performed and up to 5 protein lysates obtained from each morphologically differing region of each tumour as well as matched normal kidney. Reverse phase protein arrays (RPPA) were performed to assess the levels of multiple proteins relevant to ccRCC pathogenesis and sunitinib activity. Appropriate statistical tests were used to examine protein heterogeneity and differential expression, including false discovery rate (FDR) correction. Kaplan-Meier method was used to correlate changes in protein expression with outcome. Results: Expression of 20 proteins has been examined to date. The range of expression in tumours normalised by matched normal renal tissue had >2-fold differences in untreated (n=8 proteins) and treated samples (n=4 proteins). Four markers displayed significantly increased inter-tumoural variance in sunitinib treated tumours compared with untreated tissue (e.g. VEGFR1, FDR P<0.05). Despite this heterogeneity, sunitinib was associated with significant expression changes for several key proteins (e.g. VEGFR2, CyclinD2; FDR P<0.05). Conclusions: Protein expression in ccRCC is heterogenous and key proteins showed significantly increased variance of expression with sunitinib therapy. Despite heterogeneity, significant changes in protein expression can be identified with sunitinib treatment and have been correlated with outcome.
Collapse
Affiliation(s)
- Grant Duncan Stewart
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Fiach O'Mahony
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Lel Eory
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Jyoti Nanda
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Alexander Laird
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Marie O'Donnell
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Peter Mullen
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Antony Riddick
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Alan McNeill
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Michael Aitchison
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Dan Berney
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - John Peters
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Andrea Rockall
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Anju Sahdev
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Axel Bex
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Dana Faratian
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Simon Chowdhury
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - David Harrison
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Ian Overton
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | - Thomas Powles
- University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetics Unit, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom; Whipps Cross Hospital, London, United Kingdom; St. Bartholomew's Hospital, London, United Kingdom; The Netherlands Cancer Institute, Amsterdam, Netherlands; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
| | | |
Collapse
|
16
|
Stewart GD, Nanda J, Katz E, Bowman KJ, Christie JG, Brown DJG, McLaren DB, Riddick ACP, Ross JA, Jones GDD, Habib FK. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. Biochem Pharmacol 2010; 81:203-10. [PMID: 20888325 DOI: 10.1016/j.bcp.2010.09.022] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Revised: 09/21/2010] [Accepted: 09/22/2010] [Indexed: 11/18/2022]
Abstract
Prostate cancer cells can exist in a hypoxic microenvironment, causing radioresistance. Nitric oxide (NO) is a radiosensitiser of mammalian cells. NO-NSAIDs are a potential means of delivering NO to prostate cancer cells. This study aimed to determine the effect and mechanism of action of NO-sulindac and radiation, on prostate cancer cells and stroma, under normoxia (21% oxygen) and chronic hypoxia (0.2% oxygen). Using clonogenic assays, at a surviving fraction of 10% the sensitisation enhancement ratios of radiation plus NO-sulindac over radiation alone on PC-3 cells were 1.22 and 1.42 under normoxia and hypoxia, respectively. 3D culture of PC-3 cells revealed significantly reduced sphere diameter in irradiated spheres treated with NO-sulindac. Neither NO-sulindac nor sulindac radiosensitised prostate stromal cells under normoxia or hypoxia. HIF-1α protein levels were reduced by NO-sulindac exposure and radiation at 21 and 0.2% oxygen. Alkaline Comet assay analysis suggested an increased rate of single strand DNA breaks and slower repair of these lesions in PC-3 cells treated with NO-sulindac prior to irradiation. There was a higher level of γ-H2AX production and hence double strand DNA breaks following irradiation of NO-sulindac treated PC-3 cells. At all radiation doses and oxygen levels tested, treatment of 2D and 3D cultures of PC-3 cells with NO-sulindac prior to irradiation radiosensitised PC-3, with minimal effect on stromal cells. Hypoxia response inhibition and increased DNA double strand breaks are potential mechanisms of action. Neoadjuvent and concurrent use of NO-NSAIDs have the potential to improve radiotherapy treatment of prostate cancer under normoxia and hypoxia.
Collapse
Affiliation(s)
- Grant D Stewart
- Prostate Research Group, Department of Urology, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Stewart GD, Nanda J, Brown DJG, Riddick ACP, Ross JA, Habib FK. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer 2009; 124:223-32. [PMID: 18924134 DOI: 10.1002/ijc.23934] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Nitric oxide-donating non-steroidal anti-inflammatory drugs are safer than traditional NSAIDs and inhibit the growth of prostate cancer cells with greater potency than NSAIDs. In vivo, prostate cancer deposits are found in a hypoxic environment which induces resistance to chemotherapy. The aim of this study was to assess the effects and mechanism of action of a NO-NSAID called NO-sulindac on the PC-3 prostate cancer cell line under hypoxic conditions. NO-sulindac was found to have pro-apoptotic, cytotoxic, and anti-invasive effect on PC-3 cells under normoxia and hypoxia. NO-sulindac was significantly more cytotoxic than sulindac at all oxygen levels. The sulindac/linker and NO-releasing subunits both contributed to the cytotoxic effects of NO-sulindac. Resistance of PC-3 cells to NO-sulindac was induced as the oxygen concentration declined. Hypoxia-induced chemoresistance was reversed by knocking-down hypoxia-inducible factor-1alpha (HIF-1alpha) mRNA using RNAi. Nuclear HIF-1alpha levels were upregulated at 0.2% oxygen but reduced by treatment with NO-sulindac, as was Akt phosphorylation. NO-sulindac treatment of hypoxic PC-3 cells transfected with a reporter construct, downregulated activation of the hypoxia response element (HRE) promoter. Co-transfection of PC-3 cells with the HRE promoter reporter construct and myr-Akt (constitutively active Akt) plasmids reversed the NO-sulindac induced reduction in HRE activation. Real-time polymerase chain reaction analysis of hypoxic, NO-sulindac treated PC-3 cells showed downregulation of lysyl oxidase and carbonic anhydrase IX mRNA expression. Collectively, these novel findings demonstrate that NO-sulindac directly inhibits the hypoxia response of PC-3 prostate cancer cells by inhibiting HIF-1alpha translation via the Akt signalling pathway. The ability of NO-sulindac to inhibit tumour adaption to hypoxia has considerable relevance to the future management of prostate cancer with the same cellular properties as PC-3.
Collapse
Affiliation(s)
- Grant D Stewart
- Prostate Research Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
Oestrogens have been implicated as a cause of benign prostatic hyperplasia (BPH). Previous animal studies led to the hypothesis that oestrogens can stimulate prostate growth, resulting in hyperplasia of the gland. In humans, the precise role of oestrogens in BPH pathogenesis is currently unclear. We investigated the direct effects of oestradiol on the proliferation of BPH-derived prostate cells in culture. Oestradiol (10(-7) and 10(-6) M) moderately increased the proliferation of stromal cells in culture; this stimulation was antagonised by anti-oestrogen ICI 182 780, indicating an oestrogen receptor (ER)-mediated mechanism. By contrast, oestradiol had no effects on the proliferation of epithelial cells in culture. Parameters that can determine the response of stromal cells to oestrogens, including expression of the two ER subtypes and aromatase activity, were investigated. ER beta expression in stromal cells in culture was demonstrated by immunohistochemistry and western blot analysis, and was confirmed by semi-quantitative RT-PCR showing higher expression of ER beta than ER alpha mRNA in stromal cells. Aromatase, the enzyme that converts androgen precursors to oestrogens, was also examined. Aromatase mRNA and activity were detected in stromal, but not epithelial cells in culture, suggesting a mechanism whereby oestrogen concentrations can be regulated in the BPH stroma. Taken together, these findings support the hypothesis that oestrogens play a role in the pathogenesis of BPH, a disease characterised predominantly by stromal overgrowth.
Collapse
Affiliation(s)
- Clement K M Ho
- Prostate Research Group, University of Edinburgh Cancer Research Centre, Western General Hospital, 4th floor MRC Human Genetics Building, Crewe Road South, Edinburgh EH4 2XU, UK
| | | | | | | |
Collapse
|
19
|
Stewart GD, Nanda J, Christie JG, Brown DJG, Riddick ACP, Ross JA, Habib FK. THE POTENTIAL ROLE OF NITRIC OXIDE DONATING NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NO-NSAIDs) AS NEOADJUVENT THERAPY PRIOR TO IRRADIATION OF HYPOXIC PROSTATE CANCER CELLS. J Urol 2008. [DOI: 10.1016/s0022-5347(08)60130-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Sapra S, Nanda J, Pietryga JM, Hollingsworth JA, Sarma DD. Unraveling Internal Structures of Highly Luminescent PbSe Nanocrystallites Using Variable-Energy Synchrotron Radiation Photoelectron Spectroscopy. J Phys Chem B 2006; 110:15244-50. [PMID: 16884241 DOI: 10.1021/jp061885p] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The internal structure of PbSe nanocrystals was deduced using synchrotron X-ray photoemission spectroscopy for three different sizes of nanocrystals. The photoemission data revealed the layered structure of PbSe nanocrystals with the crystalline PbSe core surrounded by a nonstoichiometric Pb(1-x)Se shell, finally passivated by a capping agent in the outermost layer. A detailed analysis of the experimental data yielded quantitative information on the thickness of three different layers, which is unavailable through any other technique; moreover, the overall sizes of the nanocrystals probed by transmission electron microscopy were in agreement with the corresponding quantity obtained in the present experiment. The present results provide a plausible explanation for the strong variation in the photoluminescence intensity with size observed for these nanocrystals.
Collapse
Affiliation(s)
- Sameer Sapra
- Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore 560012, India
| | | | | | | | | |
Collapse
|
21
|
Affiliation(s)
- V. O. Saik
- Department of Chemistry, Stanford University, Stanford, California 94305
| | - A. A. Goun
- Department of Chemistry, Stanford University, Stanford, California 94305
| | - J. Nanda
- Department of Chemistry, Stanford University, Stanford, California 94305
| | - Koichiro Shirota
- Department of Chemistry, Stanford University, Stanford, California 94305
| | - H. L. Tavernier
- Department of Chemistry, Stanford University, Stanford, California 94305
| | - M. D. Fayer
- Department of Chemistry, Stanford University, Stanford, California 94305
| |
Collapse
|
22
|
Sapra S, Nanda J, Anand A, Bhat SV, Sarma DD. Optical and magnetic properties of manganese-doped zinc sulfide nanoclusters. J Nanosci Nanotechnol 2003; 3:392-400. [PMID: 14733149 DOI: 10.1166/jnn.2003.211] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
We report the synthesis of fixed-size ZnS nanoclusters approximately 24 A in diameter with varying manganese concentrations. Various samples of Zn1-x MnxS, with x = 0, 0.02, 0.055, 0.09, and 0.13, have been prepared and characterized using X-ray diffraction, energy-dispersive analysis of X-rays, UV absorption, fluorescence emission and excitation, electron paramagnetic resonance (EPR), and magnetic susceptibility measurements. The manganese ions are found to substitute Zn randomly without giving rise to any clustering of Mn sites, as seen from EPR and magnetic susceptibility results. Our studies reveal that the band gap of the doped nanoclusters passes through a maximum as the manganese concentration is varied. Also, we observe orange emission from Mn2+ ions in the doped ZnS nanoclusters, apart from the blue emission characteristic of the ZnS defect states. The relative intensity of the orange emission compared with the blue varies with the manganese concentration in a nonmonotonic way. The inverse of susceptibility temperature plots can be plotted onto a universal curve by simple multiplicative constants, thus showing that the magnetic interactions between Mn2+ ions are weak.
Collapse
Affiliation(s)
- Sameer Sapra
- Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore 560012, India
| | | | | | | | | |
Collapse
|
23
|
Abstract
A one-pot synthesis is reported of water-soluble cadmium sulfide nanoclusters capped with cysteine ester, with an average size of 2.0 nm and fluorescing in the blue region, establishing the possibility of using these as fluorescent biological probes.
Collapse
Affiliation(s)
- S Sapra
- Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore-560 012, India.
| | | | | | | | | |
Collapse
|
24
|
Abstract
School nurses play an important role in identifying children with asthma and providing care during school hours. Educational programs designed to improve nurses' asthma knowledge and practices have concentrated on urban settings. The purpose of this investigation was to determine asthma-related practices and educational needs of rural school nurses. A survey about asthma was mailed to school nurses in all counties of the state of Maryland and in Washington, D.C. Responses were compared between rural Maryland counties and counties from the remainder of Maryland and Washington, D.C. The survey addressed attitudes and beliefs, function and roles, medication administration, and educational needs about asthma. We found that rural nurses used peak flow meters less often to assess and monitor asthma, requested fewer referrals for asthma, had fewer interactions with health room assistants, and had reduced access to asthma educational resources. Also, they provided less asthma education in the schools than other school nurses. These results suggest a need for comprehensive asthma educational programs in rural areas that are based on national guidelines, and that address the unique needs of rural school nurses. These programs should also emphasize the need for open communication between rural school nurses, health room assistants, primary care providers, and parents/caregivers.
Collapse
Affiliation(s)
- K Huss
- School of Nursing, The Johns Hopkins University, Baltimore, Maryland, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
From October 1994 through September 1998, the American College of Nurse Midwives conducted a nationwide Domestic Violence Education Project. The project aimed to encourage universal screening for domestic violence among all women being seen for care. A four-pronged set of objectives was used, including policy, basic education, continuing education, and advocacy/activism. A description of the project and the results of the project evaluation, including replicable features, are presented. Process and outcome evaluations were performed using both quantitative and qualitative data. Surveys, interviews, and site visits formed the basis for the evaluation of the policy reform, education program, and advocacy components. Pretests and posttests of training participants formed the basis of the evaluation of the continuing education component. All project objectives were met. Policy reform occurred as expected. Changes were noted in education programs in both didactic content and clinical exposure. Changes in clinical behavior as assessed by the pretests and posttests look promising, although numbers of respondents at 12 and 24 months after training are small. Participants reported an increase in advocacy and activism. The Domestic Violence Education Project seems to be a successful and somewhat replicable model for changing attitudes about a health topic (among providers) with possible implications for clinical practice.
Collapse
Affiliation(s)
- P Paluzzi
- Maternal and Child Health Department, Johns Hopkins School of Hygiene, USA
| | | | | |
Collapse
|
26
|
Gaston-Johansson F, Fall-Dickson JM, Nanda J, Ohly KV, Stillman S, Krumm S, Kennedy MJ. The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs 2000; 23:277-85. [PMID: 10939175 DOI: 10.1097/00002820-200008000-00004] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Patients with breast cancer who undergo autologous bone marrow/peripheral blood stem cell transplantation (ABMT) cope not only with a life-threatening medical treatment, but also with multiple, interrelated symptoms including pain, fatigue, psychological distress, and nausea. The purpose of this study was to determine, in a randomized controlled clinical trial, whether a comprehensive coping strategy program (CCSP) was effective in significantly reducing pain, fatigue, psychological distress, and nausea in patients with breast cancer who underwent ABMT. The CCSP was composed of preparatory information, cognitive restructuring, and relaxation with guided imagery. Randomization placed 52 patients in the CCSP treatment group and 58 patients in the control group. The CCSP was found to be effective in significantly reducing nausea as well as nausea combined with fatigue 7 days after the ABMT when the side effects of treatment were most severe. These results are important given the high incidence of nausea and fatigue in the ABMT population. The CCSP-treated group experienced mild anxiety as compared with the control group who reported moderate anxiety. The greatest effectiveness of CCSP may correspond to the time of the greatest morbidity for patients with breast cancer who have undergone ABM.
Collapse
Affiliation(s)
- F Gaston-Johansson
- International and Extramural Programs, Johns Hopkins University School of Nursing, Baltimore, Maryland 21205-2110, USA
| | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The authors conducted a cohort study of low income women to determine the effect of physical activity on the risk of preterm birth. Women were sampled prenatally from four clinic sites and were scheduled for delivery at the University of Maryland Medical Systems (UMMS). Women who delivered infants at UMMS but who had received no prenatal care were also eligible. Preterm delivery was defined as a delivery prior to 37 completed weeks gestation. After adjusting for confounders, the odds of preterm delivery were increased for women who climbed stairs > or = 10 times per day (odds ratio (OR) = 1.60, 95% confidence interval 1.05-2.46) and for women who engaged in purposive walking > or = 4 days per week (OR = 2.10, 95% CI 1.38-3.20). Leisure-time exercise (> or = 60 days in the first and second trimesters combined) had a protective effect on preterm delivery (OR = 0.51, 95% CI 0.27-0.95). Television viewing had a U-shaped relation with preterm delivery (ORs (95% CI): < 15 hours, 2.09 (1.21-3.61); 29-42 hours, 1.50 (0.84-2.67); > 42 hours, 3.05 (1.75-5.40)). While the results support current recommendations regarding leisure-time activities, activities of daily living appear to increase risk of preterm delivery among low income women. These findings and those for television watching warrant further investigation.
Collapse
Affiliation(s)
- D P Misra
- Department of Maternal and Child Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205, USA
| | | | | | | | | |
Collapse
|
28
|
Starfield B, Cassady C, Nanda J, Forrest CB, Berk R. Consumer experiences and provider perceptions of the quality of primary care: implications for managed care. J Fam Pract 1998; 46:216-226. [PMID: 9519019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
BACKGROUND The purpose of this study was to determine the extent to which consumer and provider reports of primary care differ according to particular characteristics of the primary care setting. METHODS A random sample of consumers was surveyed by telephone in a defined geographic area of Washington, DC, to determine their experiences with care provided to a randomly chosen child. The primary care provider of each respondent was sent a parallel survey. Scores were obtained for each of two subdomains in the four cardinal primary care domains (first contact, longitudinality, comprehensiveness, and coordination) and for three related domains (family centeredness, community orientation, and cultural competence). Differences between settings that did or did not impose limitations on autonomy for referrals and between fee-for-service and capitated settings were ascertained. RESULTS Both consumers and their providers in settings characterized by high degrees of limitation on physician autonomy or by capitation reported better first-contact accessibility and a greater range of services available than did consumers in settings with low degrees of limitation, or by fee-for-service reimbursements to physicians. Consumers but not providers reported better family centeredness in these settings. Most other differences favored these settings as well, but these were not consistently statistically significant for both providers and consumers in both types of settings. CONCLUSIONS The quality of primary care services in different settings can be ascertained by using an instrument with demonstrated reliability and convergent validity. Although certain types of settings, in the particular geographic area studied, appear to perform better in several key aspects of the primary care, replication of the study in other areas would be useful judging the performance of the newer types of settings to be superior to more conventional care for general populations.
Collapse
Affiliation(s)
- B Starfield
- Department of Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA.
| | | | | | | | | |
Collapse
|
29
|
Strobino DM, Ensminger ME, Kim YJ, Nanda J. THE AUTHORS REPLY. Am J Epidemiol 1996. [DOI: 10.1093/oxfordjournals.aje.a008825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Baigis-Smith J, Gordon D, McGuire DB, Nanda J. Healthcare needs of HIV-infected persons in hospital, outpatient, home, and long-term care settings. J Assoc Nurses AIDS Care 1995; 6:21-33. [PMID: 8580467 DOI: 10.1016/s1055-3290(05)80011-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
In this descriptive study, healthcare needs reported by 386 HIV-infected persons from all risk categories and their primary nurses from four care settings (hospital, outpatient, long-term care, and home) are identified. Healthcare needs were classified into four domains of nursing practice using a conceptual framework from community health nursing--physiologic, psychosocial, health behaviors, environmental--and were assessed using the Healthcare Needs Scale for Patients with HIV/AIDS. Nurses' perceptions of major healthcare needs across all settings centered around decreased physical endurance, limited physical mobility, and sensory deficits. Patients' needs focused on financial issues. The results reflect the multidimensional nature of this infection and provide direction for clinical practice.
Collapse
Affiliation(s)
- J Baigis-Smith
- Georgetown University School of Nursing, Washington, DC, USA
| | | | | | | |
Collapse
|
31
|
Abstract
The authors studied three hypothesized explanations for reduced birth weights of infants born to US adolescent mothers--social disadvantage, biologic immaturity, and unhealthy behaviors during pregnancy. A hierarchical regression analysis was pursued to evaluate these explanations using data from the National Longitudinal Study of Youth on 1,754 first births between 1979 and 1983 to women aged 14-25 years at the time of birth. The birth weights of infants of mothers aged 14-17, 18-19, and 20-23 years were 133, 54, and 88 g less than for infants of mothers aged 23-25. The regression results indicate that the reduced birth weights of infants born to young mothers, particularly women aged 14-17, were related to their disadvantaged social environment. When adjustment was made for poverty and minority status, there were no maternal age differences in birth weight. The reduced birth weights were not related to the young woman's health behaviors during pregnancy or her biologic characteristics. Ethnicity, poverty status, age at menarche, maternal height, net maternal weight gain, and smoking during pregnancy had an independent effect on birth weight in this sample of young women.
Collapse
Affiliation(s)
- D M Strobino
- Department of Maternal and Child Health, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
| | | | | | | |
Collapse
|
32
|
|
33
|
Abstract
We studied the relationship of young maternal age with infant hospitalization using data from the National Longitudinal Survey of Youth for 3,130 infants born between 1979 and 1983 to mothers aged 14-25 years. Data on the mothers were first collected in 1979 and yearly thereafter. Data on their children were collected starting in 1982. Logistic regressions of infant hospitalization rates were estimated for first and second and higher births. The odds of infant hospitalization during the first year of life increased with decreasing maternal age, even with adjustment for sociodemographic characteristics, preventive health-care practices, and newborn health status, factors hypothesized to explain the maternal age effect. The maternal age relationship with hospitalization differed by birth order; among second and higher births, the odds of hospitalization was increased only for infants of mothers aged 20-22 years. Male infants, infants with a first well-baby visit after the first month of life, with birth weights between 1501 and 2500 g, and with nursery stays longer than 1 week also had increased odds of hospitalization. Ethnicity, grandmother's education, poverty status, mother's school enrollment, and family composition were not related to the odds of hospitalization, nor was smoking during pregnancy when adjustment was made for birth weight and length of nursery stay.
Collapse
Affiliation(s)
- D M Strobino
- Department of Maternal and Child Health, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205
| | | | | | | |
Collapse
|
34
|
Das D, Nanda J, Kothari ML, Kothari DP. AUTOMATIC GENERATION CONTROL OF A HYDROTHERMAL SYSTEM WITH NEW AREA CONTROL ERROR CONSIDERING GENERATION RATE CONSTRAINT. ACTA ACUST UNITED AC 1990. [DOI: 10.1080/07313569008909490] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Abstract
In the United States, there is growing concern that adolescents are at increasing risk for HIV-1 infection due to recreational substance use and sexual activity. Self-report questionnaires from a sample of 224 incarcerated delinquents quantified associations between drug use, sex, and other behaviors which risk HIV-1 infection. High rates of substance use and HIV-risking behaviors were found. Significant correlations between levels of substance use and both behavioral and attitudinal barriers to HIV/AIDS prevention programming were observed. This evidence and other subgroup differences in denial of vulnerability and in practice of preventive behaviors indicate the need for different approaches to prevention. An integrated HIV/AIDS and substance misuse prevention program is discussed as a viable alternative to the usual knowledge-enhancing programs.
Collapse
Affiliation(s)
- J Rolf
- Johns Hopkins School of Hygiene and Public Health, Baltimore, MD 21205
| | | | | | | | | |
Collapse
|
36
|
Bone LR, Mamon J, Levine DM, Walrath JM, Nanda J, Gurley HT, Noji EK, Ward E. Emergency department detection and follow-up of high blood pressure: use and effectiveness of community health workers. Am J Emerg Med 1989; 7:16-20. [PMID: 2914043 DOI: 10.1016/0735-6757(89)90077-6] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
This study introduced trained paraprofessionals, community health workers (CHWs), into the emergency department (ED) to supplement providers' routine efforts in high blood pressure (HBP) detection, treatment, and follow-up among high-risk black men. In a demonstration project over a 2-year period, CHWs provided (1) BP and pulse measurements, and educational counseling regarding HBP and cardiovascular risk factors; (2) telephone preappointment reminders to improve ED follow-up visit rates; and (3) recontact of patients failing to show for their ED follow-up visits to improve return rates even after missed BP appointments. Results of preappointment reminders by CHWs showed a 19% improvement in appointment keeping (P less than .001). With a sample of patients who had failed to return for a follow-up visit, CHW contact was also effective, showing an overall improvement rate of 7% (P less than .001). The results reported support the idea that individuals from the community, trained as paraprofessionals, can improve appointment keeping as well as be useful in assisting in screening and counseling for chronic conditions within the ED. These CHWs are seen as having the additional advantage of enhancing the integration of the ED, the community, and continuing care sites. The approaches used in this study should be applicable and may serve as a model for the approach to other chronic conditions experienced in urban high-risk communities.
Collapse
Affiliation(s)
- L R Bone
- Department of Health Policy and Management, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205
| | | | | | | | | | | | | | | |
Collapse
|
37
|
|